This Lung Cancer SPORE application is a competing renewal application submitted by the Vanderbilt-lngram Cancer Center and its affiliated institutions. Cancer is now the number one killer of Americans, and lung cancer is the number one cause of cancer death, causing the deaths of more people than breast, colon, and prostate cancers combined. The Vanderbilt-lngram Cancer Center SPORE application in lung cancer is composed of investigators with expertise in proteomics, cellular and molecular biology, epidemiology, pathology, pulmonary medicine and medical, radiation, and surgical oncology committed to translational research with the goal of reducing the incidence, morbidity and mortality of lung cancer. We are applying a broad range of state-of-the-art technologies, including leading edge protein mass spectrometry, expertise in signal transduction, and in eicosanoid biology, as well as innovative bioinformatics and statistical analyses to this problem. We have assembled a multidisciplinary team of internationally recognized basic and clinical investigators into a cohesive program with a history of progress in the translation of laboratory findings into the clinic and back, as well as a track record of extensive collaborations with the other lung SPOREs, multiple cooperative groups, as well as the two other SPOREs at Vanderbilt. We have demonstrated flexibility and responsiveness in our program to optimize achieving the broader goals of our SPORE. The overall goal of our program is to define complex pathways and important intermediates in these pathways to help in the early detection and optimal treatment of patients with lung cancer. Our program is focused on elements of these pathways of potential utility both as clinically useful biomarkers for early detection, prediction and prognostication, but also as potential direct therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090949-10
Application #
8136279
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Ujhazy, Peter
Project Start
2001-06-28
Project End
2013-03-31
Budget Start
2011-04-01
Budget End
2013-03-31
Support Year
10
Fiscal Year
2011
Total Cost
$2,185,000
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Edmonds, Mick D; Boyd, Kelli L; Moyo, Tamara et al. (2016) MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J Clin Invest 126:349-64
Boutaud, Olivier; Sosa, I Romina; Amin, Taneem et al. (2016) Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila) 9:855-865
Pulliam, Stephanie R; Uzhachenko, Roman V; Adunyah, Samuel E et al. (2016) Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett 169:61-72
Hassanein, Mohamed; Hight, Matthew R; Buck, Jason R et al. (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18:18-23
Whang, Y M; Park, S I; Trenary, I A et al. (2016) LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene 35:856-66
de Aquino, Maria Teresa P; Malhotra, Anshu; Mishra, Manoj K et al. (2015) Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 166:117-33
Mitra, Ramkrishna; Lin, Chen-Ching; Eischen, Christine M et al. (2015) Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: a lung cancer study. RNA 21:1055-65
Hassanein, Mohamed; Qian, Jun; Hoeksema, Megan D et al. (2015) Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer 137:1587-97
Galvani, Elena; Sun, Jing; Leon, Leticia G et al. (2015) NF-?B drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 6:42717-32
Luu, Hung N; Wen, Wanqing; Li, Honglan et al. (2015) Are dietary antioxidant intake indices correlated to oxidative stress and inflammatory marker levels? Antioxid Redox Signal 22:951-9

Showing the most recent 10 out of 212 publications